Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12109348rdf:typepubmed:Citationlld:pubmed
pubmed-article:12109348lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:12109348lifeskim:mentionsumls-concept:C0279025lld:lifeskim
pubmed-article:12109348lifeskim:mentionsumls-concept:C0449243lld:lifeskim
pubmed-article:12109348pubmed:issue1lld:pubmed
pubmed-article:12109348pubmed:dateCreated2002-7-11lld:pubmed
pubmed-article:12109348pubmed:abstractTextThe history of the use of hormonal therapy to treat prostrate cancer is outlined, focusing on such treatments and disease scenarios as diethylstilboestrol therapy, androgen ablation alone or in conjunction with radiation, and the treatment of minimal disease burdens. Studies have pointed to the benefits of initiating androgen ablation therapy earlier in the treatment of prostate cancer; the greatest benefits of anti-androgen therapy may be gained when only tiny amounts of prostate cancer are present.lld:pubmed
pubmed-article:12109348pubmed:languageenglld:pubmed
pubmed-article:12109348pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12109348pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12109348pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12109348pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12109348pubmed:statusMEDLINElld:pubmed
pubmed-article:12109348pubmed:monthFeblld:pubmed
pubmed-article:12109348pubmed:issn0094-0143lld:pubmed
pubmed-article:12109348pubmed:authorpubmed-author:MessingEdward...lld:pubmed
pubmed-article:12109348pubmed:authorpubmed-author:SessionsAnnet...lld:pubmed
pubmed-article:12109348pubmed:issnTypePrintlld:pubmed
pubmed-article:12109348pubmed:volume29lld:pubmed
pubmed-article:12109348pubmed:ownerNLMlld:pubmed
pubmed-article:12109348pubmed:authorsCompleteYlld:pubmed
pubmed-article:12109348pubmed:pagination223-7, xilld:pubmed
pubmed-article:12109348pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:meshHeadingpubmed-meshheading:12109348...lld:pubmed
pubmed-article:12109348pubmed:year2002lld:pubmed
pubmed-article:12109348pubmed:articleTitleTiming hormonal therapy in prostate cancer.lld:pubmed
pubmed-article:12109348pubmed:affiliationDepartment of Urology, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA.lld:pubmed
pubmed-article:12109348pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12109348pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12109348lld:pubmed